Generic Afinitor is launched in US by Par Pharma /Endo.
Endo International plc announced that one of its operating companies, Par Pharmaceutical (Par), has received approval for and launched generic Afinitor (everolimus) 2.5 mg, 5 mg and 7 mg tablets. Product is available for immediate shipping.
"We are pleased to bring the first generic Afinitor to market and provide patients with a lower-cost option," said Domenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics at Endo. "This launch is a testament to Par's expertise in manufacturing technically challenging products while maintaining excellence in quality."
According to IQVIA data, sales for Afinitor 2.5 mg, 5mg and 7mg tablets were approximately $412 million over the last four quarters.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins